Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to pitolisant for the treatment of idiopathic hypersomnia (IH).
https://finance.yahoo.com/news/harmony-biosciences-announces-us-food-120500206.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.